Home > Resources > Whitepapers > INTRODUCING BIO-BASED AND SUSTAINABLE COMPONENTS TO LONG-STANDING SUPPLY CHAINS.

INTRODUCING BIO-BASED AND SUSTAINABLE COMPONENTS TO LONG-STANDING SUPPLY CHAINS.

March 21, 2019

Introducing bio-based and sustainable components to long-standing supply chains.

Spotlight

PharmaSynth

PharmaSynth Pty Ltd is one of Australia’s most experienced biopharmaceutical contract manufacturing organisations. PharmaSynth is conveniently located in Brisbane, Queensland. We offer an inclusive set of services including GMP manufacture of recombinant proteins, vaccines and synthetic molecules for human and veterinary use. We can produce GMP material for pre-clinical studies and clinical trial material batches for Phase 1, 2 and 3 clinical studies.

OTHER WHITEPAPERS

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

Early engagement and regulatory considerationsfor biotech

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

Microfluidics: Big developments on thesmall scale

whitePaper | February 23, 2023

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

Long-term follow-up studies of cell and gene therapies

whitePaper | September 29, 2022

The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2